Targeting the S and G2 checkpoint to treat cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drug Discovery Today

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2011.12.009PMID 22192883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

  2012cited by this paper
• Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

  2011cited by this paper
• Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.

  2011cited by this paper
• Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

  2011cited by this paper
• Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

  2011cited by this paper
• Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

  2011cited by this paper
• Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

  2011cited by this paper
• Anticancer therapy with checkpoint inhibitors: what, where and when?

  2011cited by this paper
• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

  2011cited by this paper
• A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

  2011cited by this paper
• Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

  2011cited by this paper
• Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase*

  2011cited by this paper
• ATR autophosphorylation as a molecular switch for checkpoint activation.

  2011cited by this paper
• Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

  2011cited by this paper
• Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.

  2011cited by this paper
• ATR: a master conductor of cellular responses to DNA replication stress.

  2011cited by this paper
• Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

  2010cited by this paper
• Epigenetic Modifications in Double-Strand Break DNA Damage Signaling and Repair

  2010cited by this paper
• Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells

  2010cited by this paper
• Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}.

  2010cited by this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cited by this paper
• In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

  2010cited by this paper
• A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

  2010cited by this paper
• ATR mediates cisplatin resistance in a p53 genotype-specific manner

  2010cited by this paper
• Prospects for the Use of ATR Inhibitors to Treat Cancer

  2010cited by this paper
• The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

  2010cited by this paper
• Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

  2010cited by this paper
• p53‐dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors

  2010cited by this paper
• Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

  2010cited by this paper
• Importance of DNA damage checkpoints in the pathogenesis of human cancers.

  2010cited by this paper
• The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

  2010cited by this paper
• Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

  2010cited by this paper
• Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

  2010cited by this paper
• A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

  2010cited by this paper
• H2AX: functional roles and potential applications

  2009cited by this paper
• Cardiotoxicity induced by tyrosine kinase inhibitors

  2009cited by this paper
• Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin

  2009cited by this paper
• Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response

  2009cited by this paper
• CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

  2009cited by this paper
• Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis

  2009cited by this paper
• PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

  2009cited by this paper
• Enhanced Systemic Immune Reactivity to a Basal Cell Carcinoma Associated Antigen Following Photodynamic Therapy

  2009cited by this paper
• Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation via derepression of Chk1 catalytic activity

  2009cited by this paper
• Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

  2009cited by this paper
• Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

  2009cited by this paper
• DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

  2008cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008cited by this paper
• Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control

  2008cited by this paper
• Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil

  2008cited by this paper
• Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  2008cited by this paper
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850)

  2006cited by this paper
• The ATM-mediated DNA-damage response: taking shape.

  2006cited by this paper
• A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress

  2006cited by this paper
• Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis.

  2006cited by this paper
• Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery.

  2006cited by this paper
• Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks*

  2006cited by this paper
• A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

  2006cited by this paper
• Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

  2006cited by this paper
• Phosphorylation of Chk1 by ATR Is Antagonized by a Chk1-Regulated Protein Phosphatase 2A Circuit

  2006cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006cited by this paper
• p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine

  2006cited by this paper
• Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint

  2005cited by this paper
• The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons*

  2005cited by this paper
• The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

  2005cited by this paper
• A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

  2005cited by this paper
• Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

  2005cited by this paper
• G1 cell-cycle control and cancer

  2004cited by this paper
• Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53

  2004cited by this paper
• Apoptosis Resistance of MCF-7 Breast Carcinoma Cells to Ionizing Radiation Is Independent of p53 and Cell Cycle Control but Caused by the Lack of Caspase-3 and a Caffeine-Inhibitable Event

  2004cited by this paper
• Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation

  2004cited by this paper
• Is There a Link Between DNA Polymerase Beta and Cancer?

  2004cited by this paper
• EGFR Autocrine Signaling in a Compliant Interstitial Space: Mechanotransduction from the Outside In

  2004cited by this paper
• A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome

  2003cited by this paper
• Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer

  2003cited by this paper
• Caffeine Inhibits Checkpoint Responses without Inhibiting the Ataxia-Telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) Protein Kinases*

  2003cited by this paper
• Lethal Errors in Checkpoint Control: Life without Chk1

  2003cited by this paper
• Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.

  2003cited by this paper
• Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma

  2003cited by this paper
• Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line

  2002cited by this paper
• Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

  2002cited by this paper
• ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation

  2001cited by this paper
• Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism.

  2001cited by this paper
• Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

  2001cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• ATR disruption leads to chromosomal fragmentation and early embryonic lethality.

  2000cited by this paper
• Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice.

  2000cited by this paper
• Function of the c-Myc oncogenic transcription factor.

  1999cited by this paper
• Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.

  1999cited by this paper
• Anticancer drug targets: cell cycle and checkpoint control.

  1999cited by this paper
• Overexpression of a kinase‐inactive ATR protein causes sensitivity to DNA‐damaging agents and defects in cell cycle checkpoints

  1998cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.

  1995cited by this paper

• Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy.

  2025cites this paper
• The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

  2025cites this paper
• A Novel Prognostic Model of Endometrial Cancer Based on Inflammation and Lipid Metabolism Genes

  2025cites this paper
• Exosome-mediated modulation of bortezomib cytotoxicity in multiple myeloma cells: involvement of redox balance and cell cycle arrest through ketotifen treatment

  2025cites this paper
• Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

  2025cites this paper
• Targeting receptor for activated C kinase 1 with a small molecule induces mitotic catastrophe and suppresses lipid metabolic reprogramming in hepatocellular carcinoma

  2025cites this paper
• Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update

  2025cites this paper
• Modelling radiobiology

  2024cites this paper
• The dynamic role of nucleoprotein SHCBP1 in the cancer cell cycle and its potential as a synergistic target for DNA-damaging agents in cancer therapy

  2024cites this paper
• PR55α-controlled protein phosphatase 2A inhibits p16 expression and blocks cellular senescence induction by γ-irradiation

  2024cites this paper
• Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma

  2024cites this paper
• Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

  2024cites this paper
• The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma.

  2024cites this paper
• GRK2-mediated AKT activation controls cell cycle progression and G2 checkpoint in a p53-dependent manner

  2024cites this paper
• The Interaction of Calcium-Sensing Receptor with KIF11 Enhances Cisplatin Resistance in Lung Adenocarcinoma via BRCA1/cyclin B1 pathway

  2024cites this paper
• Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers.

  2023cites this paper
• Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer.

  2023cites this paper
• Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.

  2023cites this paper
• miR-656-3p inhibits melanomas in vitro and in vivo by inducing senescence via inhibiting LMNB2

  2023cites this paper
• Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review.

  2023cites this paper
• Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE

  2022cites this paper
• Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.

  2022cites this paper
• Heptamethine Cyanine–Based Application for Cancer Theranostics

  2022cites this paper
• Unprecedented Insights on Chemical and Biological Significance of Euphorbia cactus Growing in Saudi Arabia

  2022cites this paper
• Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma

  2022cites this paper
• Cell Signaling Pathways That Promote Radioresistance of Cancer Cells

  2022cites this paper
• Novel 1,3,4-oxadiazole chalcogen analogues: Synthesis and cytotoxic activity.

  2022cites this paper
• HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer

  2022cites this paper
• Discovery of pyrrolo[2,3-d]pyrimidine-based molecules as a Wee1 inhibitor template.

  2022cites this paper
• Ferroptosis-related gene ATG5 is a novel prognostic biomarker in nasopharyngeal carcinoma and head and neck squamous cell carcinoma

  2022cites this paper
• Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

  2022cites this paper
• Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.

  2021cites this paper
• DNA damage response and repair in pancreatic cancer development and therapy.

  2021cites this paper
• Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.

  2021cites this paper
• Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications

  2021cites this paper
• The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders

  2021cites this paper
• Toxic effects and mechanisms of three commonly used fungicides on the human colon adenocarcinoma cell line Caco-2

  2020cites this paper
• Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells

  2020cites this paper
• Silencing of Long Non-coding RNA ENST00000606790.1 Inhibits the Malignant Behaviors of Papillary Thyroid Carcinoma through the PI3K/AKT Pathway

  2020cites this paper
• Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants.

  2020cites this paper
• WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia

  2020cites this paper
• mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms

  2020cites this paper
• Synthesis of naphthalimide-carborane and metallacarborane conjugates: Anticancer activity, DNA binding ability.

  2019cites this paper
• Investigation of biaryl heterocycles as inhibitors of Wee1 kinase.

  2019cites this paper
• Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.

  2019cites this paper
• A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer

  2019cites this paper
• Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death

  2019cites this paper
• UBE2C overexpression in melanoma and its essential role in G2/M transition

  2019cites this paper
• Evaluation of the anti-cancer potential of Cedrus deodara total lignans by inducing apoptosis of A549 cells

  2019cites this paper
• Radiation‐activated prosurvival signaling pathways in cancer cells

  2019cites this paper
• BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition.

  2019cites this paper
• Regulation of the oocyte pool in mammals

  2019influential citation
• Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin

  2019influential citation
• Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates

  2018cites this paper
• Radiosensitization of clioquinol and zinc in human cancer cell lines

  2018cites this paper
• Carcinogenesis: recent insights in protist stem cell biology lead to a better understanding of atavistic mechanisms implied in cancer development

  2018cites this paper
• Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

  2018cites this paper
• G protein-coupled peptide receptors as molecular targets in neuroendocrine tumors

  2018cites this paper
• NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc

  2018cites this paper
• Development of Potent Pyrazolopyrimidinone‐Based WEE1 Inhibitors with Limited Single‐Agent Cytotoxicity for Cancer Therapy

  2018cites this paper
• Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro

  2018cites this paper
• Downregulation of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma.

  2018cites this paper
• Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells

  2018cites this paper
• Fabrication of rosuvastatin-loaded polymeric nanocapsules: a promising modality for treating hepatic cancer delineated by apoptotic and cell cycle arrest assessment

  2018cites this paper
• A novel anti‐cancer role of &bgr;‐apopicropodophyllin against non‐small cell lung cancer cells

  2018cites this paper
• Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality

  2018cites this paper
• Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors

  2018cites this paper
• New therapeutic strategies to treat human cancers expressing mutant p53 proteins

  2018cites this paper
• Role of Protein Linked DNA Breaks in Cancer.

  2017cites this paper
• Design, Synthesis and Evaluation of Naphthalimide Derivatives as Potential Anticancer Agents for Hepatocellular Carcinoma

  2017cites this paper
• Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer.

  2017cites this paper
• S-phase checkpoint activity and function throughout the cell cycle

  2017cites this paper
• Chk 1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN 673 in gastric cancer

  2017cites this paper
• Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of b‑Myb and miRNA34a expression.

  2017cites this paper
• Selective Kinase Inhibitors in Cancer

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• Ataxia Telangiectasia Mutated and Rad 3 Related ( ATR ) Protein Kinase Inhibition Is Synthetically Lethal in XRCC 1 Deficient Ovarian Cancer Cells

  2017cites this paper
• Targeting the ATR-CHK1 Axis in Cancer Therapy

  2017cites this paper
• Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage

  2017cites this paper
• Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.

  2017cites this paper
• Curcumin Inhibits Proliferation and Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells Via Multiple Pathways.

  2017cites this paper
• DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

  2017cites this paper
• SZRD1 is a Novel Protein that Functions as a Potential Tumor Suppressor in Cervical Cancer

  2017cites this paper
• Sensibilisation aux drogues chimiothérapeutiques des tumeurs P53 négatives par activation de la phosphatase Wip1

  2017cites this paper
• Replication Catastrophe: When a Checkpoint Fails because of Exhaustion.

  2017cites this paper
• Therapeutic Strategies against Cyclin E1 Amplified Ovarian Cancers

  2016cites this paper
• Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition

  2016cites this paper
• Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

  2016cites this paper
• Induction of G2/M phase arrest and apoptosis by ZGDHU-1 in A549 and RERF-LC-MA lung cancer cells.

  2016cites this paper
• Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.

  2016cites this paper
• Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells

  2016cites this paper
• Rapamycin‐induced autophagy sensitizes A549 cells to radiation associated with DNA damage repair inhibition

  2016cites this paper
• Carbazole Aminoalcohols Induce Antiproliferation and Apoptosis of Human Tumor Cells by Inhibiting Topoisomerase I

  2016cites this paper
• Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

  2016cites this paper
• Investigation of novel candidates for targeted therapy in melanoma

  2016cites this paper
• mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition

  2016cites this paper
• LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

  2016cites this paper
• Etude de nouvelles fonctions de la protéine checkpoint kinase 1 (Chk1) au cours de la différenciation myéloïde normale et leucémique

  2016cites this paper
• Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei

  2016cites this paper
• Transformer2 proteins protect breast cancer cells from accumulating replication stress by ensuring productive splicing of checkpoint kinase 1

  2016cites this paper